A cross-species lytic Klebsiella pneumoniae phage and its use
By developing the cross-species lysed Klebsiella pneumoniae bacteriophage RDP-EC-20056, the drug resistance problem to Klebsiella pneumoniae, E. coli and Salmonella in the prior art is solved, and efficient disease prevention and control is achieved. The application prospects of alternative antibiotics.
Patent Information
- Application Number
- CN202210898150.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-07-28
AI Technical Summary
The prior art is difficult to effectively prevent and treat livestock and poultry diseases caused by drug resistance, especially diseases caused by Klebsiella pneumoniae, E. coli and Salmonella, and the resources of cross-species phages are relatively scarce.
A transgenic lysed Klebsiella pneumoniae bacteriophage RDP-EC-20056 was developed. This phage not only has a strong lytic effect on Klebsiella pneumoniae, but also effectively lyses E. coli and Salmonella, and has High temperature tolerance and genetic stability, suitable for the preparation of drugs, feed additives and detergents for the prevention and treatment of related diseases.
The phage maintains stable titer in a 50℃ water bath with a titer of up to 10^8pfu/mL. It can effectively prevent and control pathogenic bacteria, provide the application prospect of alternative antibiotics, and reduce the resistance to pathogenic bacteria in livestock and poultry breeding The problem.
Smart Images

Figure CN115927205B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a cross-species lytic bacteriophage and its application. Background Art
[0002] Klebsiella pneumoniae is widely present in nature. It is a saprophytic fungus of humans and other mammals. It is distributed in the gastrointestinal tract, skin and nasopharynx. It is a facultative anaerobe and a resident flora or transient flora (especially in the gastrointestinal tract). In addition, it is also widely present in various environmental niches (soil, water, etc.). It is one of the most common important conditional pathogens and nosocomial infection bacteria in clinical practice. The infection caused by Klebsiella pneumoniae is characterized by a high mortality rate. Even under antibacterial treatment, the mortality rate is still as high as about 50%. Klebsiella pneumoniae is very easy to mutate, so it is relatively resistant to drugs.
[0003] Escherichia coli is a normal inhabitant of the intestines of animals, a small part of which can cause disease under certain conditions. Escherichia coli serotypes can cause gastrointestinal infections in humans or animals, mainly caused by specific fimbriae antigens, pathogenic toxins, etc. Escherichia coli disease in animals can occur in a variety of livestock, poultry, farmed economic animals, other terrestrial animals and certain aquatic animals, among which pigs and chickens are the most susceptible and the harm is very serious. Escherichia coli disease is common in newborns and young animals, manifested as enteritis, enterotoxemia, sepsis or inflammation of tissues and organs, which hinders the growth and development of livestock and poultry and causes death, resulting in great economic losses.
[0004] Salmonella is a common foodborne pathogen that is widely distributed in nature and often resides in humans and animals, especially in the intestines of poultry, livestock and pets. Poultry and livestock infected with Salmonella can cause corresponding infectious diseases, such as swine cholera and pullorum. When animals are sick, weak, malnourished, tired and their resistance is reduced, the Salmonella in the intestines can enter the blood through the mesenteric lymph nodes and lymphatic tissues and cause systemic infection or even death. Salmonellosis is a common disease in livestock and poultry, with a high incidence rate and great harm. In nature, poultry constitutes the largest single storage host of Salmonella. Among all animals, the most commonly reported Salmonella comes from poultry and poultry products.
[0005] After phages infect host bacteria, new phages are released during lysis, and a small amount of phages can have a preventive effect. The phages target the cell walls of prokaryotic microorganisms, but there are no corresponding action sites on animal and plant cells, which ensures the safety of phage use. Phages and pathogens can evolve together to prevent the emergence of bacterial resistance. Therefore, using phages to solve bacteria is a promising biological control approach.
[0006] There are many germplasm resources with high titer, high temperature resistance, acid and alkali resistance, etc., but there are few germplasm resources that can lyse Klebsiella pneumoniae, Escherichia coli and Salmonella across species. The types and number of intestinal phages directly affect the intestinal flora and its physiological state. Compared with phages that can only infect bacteria of a single genus, phages that can infect across species have more complex effects in the intestine and have a greater impact on intestinal flora and intestinal health. Summary of the invention
[0007] The purpose of the present invention is to provide a cross-species lytic Klebsiella pneumoniae phage to replace the use of antibiotics in the prevention and treatment of livestock and poultry breeding, and to solve the problem of ineffective medication due to drug resistance of pathogenic bacteria in livestock and poultry.
[0008] To achieve the above-mentioned purpose, the present invention adopts the following technical scheme: a cross-species lytic Klebsiella pneumoniae phage, the phage RDP-EC-20056, classified as Klebsiella pneumoniae phage, was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on April 20, 2022, with a deposit number of CGMCC No.45090.
[0009] Preferably, the bacteriophage has a strong lytic effect on Klebsiella pneumoniae, Escherichia coli or Salmonella.
[0010] Preferably, the present invention also provides use of the bacteriophage in preparing a drug for preventing and / or treating a disease caused by any one or more of Klebsiella pneumoniae, Escherichia coli and Salmonella.
[0011] Preferably, the present invention also provides use of the bacteriophage in preparing feed, additives or health products for preventing diseases caused by Escherichia coli and / or Salmonella.
[0012] Furthermore, the present invention also provides a bactericidal composition for Klebsiella pneumoniae, Escherichia coli or Salmonella, wherein the bactericidal composition comprises the cross-species lytic Klebsiella pneumoniae phage.
[0013] Furthermore, the present invention also provides a drug for preventing and / or treating diseases caused by Escherichia coli and Salmonella, which comprises the cross-species lytic Klebsiella pneumoniae phage.
[0014] Furthermore, the present invention also provides a feed, feed additive or health product for preventing diseases caused by Escherichia coli and / or Salmonella, which comprises the cross-species lytic Klebsiella pneumoniae phage.
[0015] Furthermore, the present invention also provides a cleaner or disinfectant for livestock and poultry breeding environments, which comprises the cross-species lytic Klebsiella pneumoniae phage.
[0016] Compared with the prior art, the beneficial effects of the present invention specifically include:
[0017] (1) The bacteriophage provided by the present invention uses Escherichia coli as a host and can not only lyse Klebsiella pneumoniae, but also lyse Escherichia coli and Salmonella across species and has strong lysis activity, thus providing a material source for the industrial production of bacteriophages and having good application prospects in the prevention and control of pathogenic Escherichia coli and Salmonella in livestock and poultry.
[0018] (2) The bacteriophage provided by the present invention can maintain a stable titer after being exposed to water bath at a temperature of 50°C for 30 minutes. The titer is relatively high, which can be above 10^8 pfu / mL. It can be seen that the bacteriophage has a certain high temperature tolerance, a high titer, and is safe and effective. The optimum temperature of the bacteriophage RDP-EC-20056 is 37°C, and the highest titer reaches 8*10^9 pfu / mL.
[0019] (3) The bacteriophage provided by the present invention is a virulent bacteriophage isolated from nature. The test phage does not contain virulence genes or undesirable genes; the present invention does not perform any genetic modification on the test phage. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is an electron microscope image of bacteriophage RDP-EC-20056 in an embodiment of the present invention;
[0021] Figure 2 The results of the lysis experiment of bacteriophage RDP-EC-20056 on host bacteria BE-20055 RTD in the examples of the present invention;
[0022] Figure 3 This is a schematic diagram of the thermal stability of bacteriophage RDP-EC-20056 in an embodiment of the present invention;
[0023] Figure 4 Schematic diagram of genetic stability of bacteriophage RDP-EC-20056 in an embodiment of the present invention. DETAILED DESCRIPTION
[0024] The present invention will be further described below in conjunction with the accompanying drawings and examples. The following examples will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, several variations and improvements may be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
[0025] The present invention isolates Escherichia coli BE-20055 from poultry excrement of Zhonghui Group's breeding farm, and determines the pathogenicity and drug resistance of the Escherichia coli BE-20055 through experiments. Using Escherichia coli BE-20055 as a host, a lytic Klebsiella pneumoniae phage is isolated from poultry excrement, and the genotype of the phage is determined by the whole genome sequence.
[0026] Example 1 Isolation and identification of pathogenic bacteria and bacteriophages
[0027] (1) Isolation and identification of host Escherichia coli BE-20055
[0028] From poultry feces, the aseptic method was used to streak and separate on the CHROMagar colorimetric medium. After culturing at 37°C for 18-24h, blue or blue-green colonies with neat edges appeared on the colorimetric plate of the colon, with a diameter of about 1-2 mm. Then, typical colonies were streaked on the MacConkey medium. After culturing at 37°C for 18-24h, pink colonies appeared on the MacConkey medium with choline salt precipitation around them. Typical colonies were streaked and purified three times, and then single colonies were inoculated in 5mL of LB broth medium, and cultured at 37°C and 200rpm for 4h to obtain a uniform turbid bacterial suspension. Then, the 16sRNA molecular identification confirmed that it was Escherichia coli, and one of the strains was named Escherichia coli BE-20055 and stored in a -80°C refrigerator.
[0029] (2) Isolation and identification of bacteriophage RDP-EC-20056
[0030] The poultry feces samples used in the experiment of the present invention were collected from the breeding farm of Zhonghui Group in 2020 and used as samples for phage isolation.
[0031] Sample processing: Take an appropriate amount of poultry feces and soak it in 20 mL LB broth, centrifuge it at 10000rpm for 10 minutes to remove larger impurities and most bacteria, and then filter it with a 0.22 μm microporous filter membrane for sterilization.
[0032] Prepare mixed bacterial suspension: Take 2 mL of filtrate and 1 mL of host bacterial suspension, add to 27 mL of autoclaved LB broth medium, and then place in a 37°C incubator for overnight culture. After culture, take 3 mL, centrifuge at 10,000 rpm for 5 minutes, and then filter and sterilize with a 0.22 μm microporous filter, collect the filtrate for use, and the filtrate is the original solution to contain the bacteriophage.
[0033] Phage isolation: Use the double plate method to isolate phages. Take 0.1mL of the mixed bacterial suspension filtrate and 0.1mL of the Escherichia coli suspension, mix them evenly, add them to 3mL of 4% nutrient agar heated to 45-54℃, spread on double plates, and incubate them in a 37℃ incubator for 6-8h. Observe the results. If there are phages, there will be transparent plaques on the plates. Pick the plaques and soak them in 1mL of normal saline for 10min. Then take 0.1mL of the extract and 0.1mL of the bacterial suspension, add them to 3mL of 4% nutrient agar heated to 45-54℃, spread on double plates, and incubate them in a 37℃ incubator for 4-6h for purification. Follow this step for 2-3 times until the plaque size is uniform. A phage is obtained and named Klebsiella pneumoniae phage. The plaques formed by phage RDP-EC-20056 on double plates are 0.1mm-0.5mm in diameter, round and transparent, like Figure 2 shown.
[0034] (3) Phage RDP-EC-20056 titer determination
[0035] The purified phage was spread on a double-layer plate, and then a single plaque was taken and added to the LB liquid culture medium, and the host bacterial suspension was added at the same time. After the phage was proliferated, the proliferated liquid was centrifuged at 10000rpm for 5 minutes and then filtered with a 0.22μm microporous filter. The filtrate was diluted 10 times to 10^-10 times, and 0.1mL of the last 3 dilutions of phage dilution liquid and 0.1mL of host bacterial suspension were taken and spread on a double-layer plate to determine the phage titer. Phage titer (pfu / mL) = plaque number * dilution factor ÷ 0.1. The results showed that the plaque morphology, size and clarity were consistent, and it had typical lytic phage characteristics; the titer of the phage could reach up to 10^9pfu / mL or more.
[0036] (4) Preservation of bacteriophage RDP-EC-20056
[0037] The phage proliferation liquid was mixed with 60% glycerol in a ratio of 1:1 and stored in liquid nitrogen.
[0038] Example 2 Electron microscopic observation of bacteriophage RDP-EC-20056
[0039] Take 20 μL of liquid containing crude phage particles and drop it on the copper mesh. Let it precipitate naturally for 15 minutes, and use filter paper to absorb excess liquid from the side. Add a drop of 2% phosphotungstic acid (PTA) on the copper mesh to stain the phage for 10 minutes, then use filter paper to absorb the staining liquid from the side. After the sample is dry, observe the phage morphology using an electron microscope.
[0040] Depend on Figure 1It can be seen that the phage RDP-EC-20056 is a phage of the family Longicaudae, with a regular icosahedral head, a head diameter of about 60nm, and a tail length of 182nm.
[0041] Example 3 Genome Sequencing and Biodeposit of Bacteriophage RDP-EC-20056
[0042] After enrichment and cultivation of a single phage, centrifuge at 8000 r for 15 minutes at 4°C, add 10% PEG8000 and 0.5M NaCl and let stand overnight, then add an equal amount of chloroform to mix, let stand and stratify, centrifuge at 5000 r for 10 minutes, remove the chloroform layer and PEG layer, add restriction endonuclease digestion, and suspend the phage under gradient density cesium chloride conditions. Later, dialyze 3 times with TM buffer, each time for 30 minutes, and send to BGI Biological Sequencing Company for whole genome sequencing. The results are shown in the sequence table SEQ ID No.1, and the full length of the genome is 60913bp. It was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on April 20, 2022, with the deposit number CGMCC No.45090. The address of the deposit unit is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0043] Example 4 Determination of the optimal infection multiplicity of bacteriophage RDP-EC-20056
[0044] The phage proliferation solution and host (E. coli BE-20055) were added to LB at a multiplicity of infection of 100:1, 10:1, 1:1., 1:10., and 1:100, and the total volume of the culture system was ensured to be the same. After shaking culture at 37°C and 200 rpm for 8 hours, centrifuged at 12000 r / min for 5 minutes at room temperature, the supernatant was taken and spread on two plates to determine its titer. The results are shown in Table 1.
[0045] Table 1 Determination results of the optimal infection multiplicity of bacteriophage RDP-EC-20056
[0046] Tube No. BE-20055 Escherichia coli count (cfu / mL) RDP-EC-20056 phage count (pfu / mL) Multiplicity of infection 8h phage titer (pfu / mL) 1 10^8 10^6 100:1 8.1*10^8 2 10^8 10^7 10:1 1.5*10^8 3 10^8 10^8 1:1 5*10^8 4 10^8 10^9 1:10 2.9*10^8 5 10^7 10^9 1:100 1*10^8 6 10^6 10^9 1:1000 1*10^8
[0047] It can be seen from the data in Table 1 that when the multiplicity of infection is 100:1, after 8 hours of culture, the proliferation fluid is relatively clear and the titer is the highest, which can reach 8.1*10^8, indicating that the optimal multiplicity of infection of the Klebsiella pneumoniae phage RDP-EC-20056 of the present invention is 100:1.
[0048] Example 5 Lysis spectrum experiment of bacteriophage RDP-EC-20056
[0049] The lysis ability of Klebsiella pneumoniae phage RDP-EC-20056 was determined by the drop method. The bacteria were evenly spread on the LB plate. After drying, 5 μL of phage suspension was dropped in the center of the spread area. After incubation at 37 °C for 6 h, if transparent plaques appeared on the bacterial lawn, it was a lysable bacterium. A total of 5 serotypes of Escherichia coli, including 4 strains of O18, 2 strains of O2, 4 strains of O45, 1 strain of O1, and 1 strain of O145, were selected to perform a lysis spectrum experiment on Klebsiella pneumoniae phage RDP-EC-20056. The lysis ability is shown in Table 2. A total of 17 different serotypes of Salmonella, including Enteritidis, Typhimurium, Typhoid, Paratyphoid A, Oritamanlin, Tsongwei, Indiana, Risen, Regensen, Sanftenberg, Newland, Kentucky, Stanley, Duck Salmonella, Bloomsbury, Thompson, and Cottbus, were subjected to lysis spectrum experiments on Klebsiella pneumoniae phage RDP-EC-20056. The lysis abilities are shown in Table 3.
[0050] Table 2 Lysis of different serotypes of Escherichia coli by bacteriophage RDP-EC-20056
[0051] Serial number Serotype Cracking capacity 1 O18 ++ 2 O18 ++ 3 O18 ++ 4 O18 ++ 5 O2 + 6 O2 - 7 O45 ++ 8 O45 ++ 9 O45 ++ 10 O45 ++ 11 O1 ++ 12 O145 -
[0052] Table 3 Lysis of different serotypes of Salmonella by bacteriophage RDP-EC-20056
[0053] Serial number Serotype Cracking capacity 1 enteritis + 2 enteritis + 3 Typhimurium ++ 4 Typhoid - 5 Paratyphoid A - 6 Orita vine forest ++ 7 Tsangwe ++ 8 Indiana ++ 9 Leeson ++ 10 Regensen ++ 11 Senftenberg ++ 12 Newland ++ 13 Newland ++ 14 Kentucky ++ 15 Kentucky ++ 16 Stanley ++ 17 Stanley ++ 18 Salmonella edulis ++ 19 Bloomsbury ++ 20 Thompson ++ 21 Cottbus ++
[0054] Note: "++" means strong cleavage, "+" means possible cleavage, and "-" means no cleavage
[0055] Example 6 Determination of thermal stability of bacteriophage RDP-EC-20056
[0056] The phage stock solution was divided into EP tubes and incubated at 40℃, 50℃, 60℃ and 70℃ for 30min, then diluted 10 times with physiological saline and double-plated to determine its titer. The results are as follows: Figure 3 As shown. Figure 3 It can be seen that the activity of the phage remains stable within 50°C and the titer is above 10^8 pfu / mL.
[0057] Example 7 Stability genetic experiment of bacteriophage RDP-EC-20056
[0058] The phage RDP-EC-20056 was subcultured 15 times, and equal amounts of RDP-EC-20056 and BE-20055 were added to the culture medium for each generation. The culture time for each generation was 6 hours, and then double plates were spread to determine the titer. The results are shown in Figure 4 shown.
[0059] Depend on Figure 4It can be seen that after the phage RDP-EC-20056 was propagated for 10 generations, its titer was measured and its titer was stable above 10^9 pfu / mL, indicating that the phage has good genetic stability and is suitable for industrial production.
[0060] Example 8 Phage RDP-EC-20056 Lysis Rate Experiment
[0061] Under sterile conditions, take 1 mL of sample and 1 mL of host bacterial solution (1×10 6 CFU / mL), incubate at 37°C for 15 minutes, mix well and dilute with normal saline to 10 -1 -10 -3 Each gradient was plated with 100 μL of each gradient on a nutrient agar plate and incubated at 37°C for 24 hours. Each gradient was repeated twice. At the same time, 1 mL of saline and 1 mL of host bacterial solution (1×10 6 CFU / mL) as a blank control and repeat the above steps. Select plates with 30-300 colonies for counting. Repeat the test 3 times and take the average value.
[0062] Phage lysis rate = (1-number of colonies in the treatment group / number of colonies in the control group) × 100%.
[0063] According to calculation, the lysis rate of bacteriophage RDP-EC-20056 reached 98.8%, which has a good lysis effect on the host and is suitable for use in breeding.
[0064] Example 9 RTD experiment of bacteriophage RDP-EC-20056
[0065] Divide the plate into areas, add a drop of host bacteria (about 10 μL) in the center of each area, dry it, add a drop of phage solution of different dilutions to the spots of host bacteria, dry it, and culture it at 37℃ overnight. According to the growth status of host bacteria, those that cannot grow in a continuous piece are called CL concentration (CL concentration is the concentration of host bacteria in the environment that can completely lyse, which can be used to guide the dilution scheme of production practice).
[0066] The bacteriophage RDP-EC-20056 still had a good lysis effect on the host bacteria after being diluted -3 times.
[0067] Example 10 Method for large-scale production of bacteriophage RDP-EC-20056
[0068] The process is simple, reliable and effective, and is conducive to industrial production.
[0069] Specific steps
[0070] 1. Seed preparation
[0071] (1) Preparation of host seeds: Under sterile conditions, pick a single colony and streak it on nutrient agar medium and culture it at 37°C overnight. Then pick a single colony and place it in 5 mL LB broth medium. After shaking and incubating it at 37°C and 180 rpm for 6 hours, inoculate it into LB broth medium at a 1% inoculum and shake and incubate it at 37°C and 180 rpm for 4 hours. Store the prepared seed solution in a 4°C refrigerator for later use.
[0072] (2) Preparation of phage seeds: After appropriately diluting the stored phage seeds, take 100 μL and place them with 100 μL of host bacteria in the upper culture medium, pour into a double-layer plate, and culture at 37°C for 4-6 hours. Then scrape it with a sterile coating rod, centrifuge it at 10,000 rpm for 5 minutes, and then sterilize it through a 0.22 μm filter membrane. The collected filtrate is stored in a 4°C refrigerator for later use.
[0073] The phage and host were inoculated into LB broth at a ratio of 1% and 5%, respectively, and cultured at 37°C, 180 rpm for 6-8 h until the proliferation fluid became clear and a large amount of flocs appeared.
[0074] 2. Phage proliferation: Inoculate 2% of the host bacteria in the seed tank. After culturing for 2-3 hours, when the OD600 is 0.6-0.8, inoculate phage seeds at a 1% inoculation rate and culture for 6-8 hours until the dissolved oxygen rises and the pH tends to be stable.
[0075] Inoculate 2% of the host bacteria in the seed tank and culture for 4-5 hours until the dissolved oxygen begins to slowly decrease.
[0076] Inoculate the prepared host bacteria into a large fermentation tank at a 5% inoculation rate and culture for 2-3 hours. When the dissolved oxygen begins to slowly decrease, inoculate the phage seeds at a 5% inoculation rate, increase the ventilation volume to 1vvm, increase the rotation speed to 150rpm, and culture for 8-10 hours. When the dissolved oxygen rises, the pH rises, and the proliferation ends.
[0077] Note: Fermentation tank parameters: Seed tank 200-300rpm, 37℃, ventilation 0.6-1vvm. Fermentation tank: 120-150pm, 37℃, ventilation 0.6-1vvm.
[0078] Culture medium ingredients: yeast extract powder 0.5%, peptone 1%, beef extract 0.1%, glycerol 0.5%, sodium chloride 0.5%, potassium dihydrogen phosphate 0.1%, dipotassium hydrogen phosphate 0.1%, calcium chloride 20ppm, magnesium chloride 20ppm.
[0079] 3. Phage post-processing process
[0080] (1) Filtration: 800nm and 500nm ceramic membranes are used for filtration to remove cell debris and unlysed host bacteria. The filtration pressure is less than 0.4 MPa to reduce the damage of shear force to bacteriophages.
[0081] (2) Concentration: Use hollow fiber membrane for concentration to increase the phage titer.
[0082] (3) Stabilizer: Add 5% glycerol, 3% trehalose, 3% polysorbate, 3% sodium dihydrogen phosphate, and 2% sodium phosphate, and stir until completely dissolved.
[0083] (4) Sterilization: Use three-stage filtration (glass fiber 0.45μm, glass fiber 0.2μm, polyethersulfone 0.22μm) for sterilization.
[0084] (5) Store the filtered, sterilized phage liquid at 4°C.
[0085] It should be pointed out that the specific implementation methods are only representative examples of the present invention. Obviously, the technical solution of the present invention is not limited to the above-mentioned embodiments, and there are many variations. Those skilled in the art who can obtain the invention clearly disclosed in the present invention or without objection based on the written description of the document should be considered as the scope of protection of this patent.
Claims
1. A cross-species lytic Klebsiella pneumoniae phage, characterized in that: The phage is Klebsiella pneumoniae phage RDP-EC-20056, which was deposited in the General Microbiology Center of China National Microbiological Culture Collection on April 20, 2022, with the deposit number CGMCC No.45090.
2. The use of the cross-species lytic Klebsiella pneumoniae phage according to claim 1, characterized in that: The bacteriophage is used for preparing medicine for preventing and / or treating diseases caused by any one or both of Escherichia coli and Salmonella.
3. A bactericidal composition for Escherichia coli or Salmonella, characterized in that: The invention comprises an effective amount of the cross-species lytic Klebsiella pneumoniae phage according to claim 1.
4. A drug for preventing and / or treating diseases caused by Escherichia coli and Salmonella, characterized in that: It includes the cross-species lytic Klebsiella pneumoniae phage as claimed in claim 1.
5. A cleaner or disinfectant for livestock and poultry breeding environments, characterized in that: The invention comprises the cross-species lytic Klebsiella pneumoniae phage as claimed in claim 1.
Citation Information
Patent Citations
Freeze-drying protective agent for klebsiella pneumoniae bacteriophage and preparation method and application of agent
CN109988753A
Drug-resistant klebsiella pneumoniae phage RDP-KP-20004 and application of drug-resistant klebsiella pneumoniae phage RDP-KP-20004
CN112662634A
